Home > Insider Trading > Filing (0001127602-13-020869)

Filing Details

Accession Number:: 0001127602-13-020869
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-06-19 16:35:19
Reporting Period:: 2013-06-17

Filing Date:: 2013-06-19
Accepted Time:: 2013-06-19 16:35:19
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1022079	Quest Diagnostics Inc	DGX	Services-Medical Laboratories (8071)	161387862

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1222679	E Michael Prevoznik	C/O Quest Diagnostics Incorporated 3 Giralda Farms Madison NJ 07940	Svp & General Counsel	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2013-06-17	62,079	$40.43	107,207	No	4	M	Direct
Common Stock	Acquisiton	2013-06-17	54,667	$52.25	161,874	No	4	M	Direct
Common Stock	Acquisiton	2013-06-18	9,921	$40.43	171,795	No	4	M	Direct
Common Stock	Disposition	2013-06-17	116,746	$62.65	55,049	No	4	S	Direct
Common Stock	Disposition	2013-06-18	9,921	$62.46	45,191	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Options (Right to Buy)	Disposition	2013-06-17	62,079	$0.00	62,079	$40.43
Common Stock	Stock Options (Right to Buy)	Disposition	2013-06-17	54,667	$0.00	54,667	$52.25
Common Stock	Stock Options (Right to Buy)	Disposition	2013-06-18	9,921	$0.00	9,921	$40.43

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
9,921	2014-02-19	No	4	M	Direct
0	2014-02-12	No	4	M	Direct
0	2014-02-19	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	4,448	Indirect	401k/SDCP

Footnotes

This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 17, 2013.
This transaction was executed in multiple trades at prices ranging from $62.39 to $63.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $62.26 to $62.69. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The amount includes exempt purchases made under the Company's stock purchase plansince the date of the last filing on Form 4.
The amount includes approximately 27 shares acquired via dividend reinvestment since the date of the last filing on Form 4 pursuant to a dividend reinvestment plan, sponsored by a broker-dealer, that essentially mirrors a dividend reinvestment plan sponsored by the registrant.
These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k) and/or Supplemental Deferred Compensation Plan. The information was obtain from the plan administrator as of a recent date. The number of shares is based on the account balance of the Company stock fund under the plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.
The options vested in three annual installments on February 19, 2005, February 19, 2006 and February 19, 2007.
The options vested in three annual installments on February 12, 2008, February 12, 2009 and February 12, 2010.